COVID-19 Hastasında Alt Ekstremite İskemisinde Femoral Blok Uygulaması

Authors

Kamuran Uluç
https://orcid.org/0000-0001-6128-0462

Synopsis

This study presents the successful treatment process of a 44-year-old male patient who developed severe acute respiratory distress syndrome (ARDS) and dissemination intravascular coagulation (DIC) following COVID-19 pneumonia, resulting in circulatory impairment and ischemia in his left lower extremity. Intubated and monitored in the intensive care unit under prone positioning, the patient exhibited coldness, discoloration, and weakened pulses below the left knee. Doppler ultrasonography revealed partial thrombosis and reduced blood flow in the left popliteal artery. To combat cytokine storm (MAS) features, the patient received cytokine-filtered continuous renal replacement therapy (CRRT), immune plasma fresh frozen plasma (IP-FFP), tocilizumab, and heparin therapy. To resolve the extremity ischemia, ultrasound-guided femoral regional nerve blocks using bupivacaine were performed four times at 24-hour intervals. Responding well to the therapy, the patient's oxygenation improved, eliminating the need for prone positioning; he was successfully extubated on the 10th day and transferred to the general ward on the 14th day. Follow-up CT angiography showed no arterial stenosis, demonstrating that the femoral block application played a critical role in preventing limb amputation by inducing vasodilation and restoring peripheral perfusion.

References

Li F. Structure, Function, and Evolution of Coronavirus Spike Proteins. Annu Rev Virol 2016;3:237–61.

Pachlopnik Schmid J, Côte M, Ménager MM, et al. Inherited defects in lymphocyte cytotoxic activity. Immunol Rev 2010;235:10-23.

Toniatia P, Pivab S, Cattalinid M. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy. Autoimmun Rev. 2020 Jul;19(7):102568. doi: 10.1016/j.autrev.2020.102568.

Sağlık Bakanlığı güncel COVİD-19 rehberi https://covid19.saglik.gov.tr/TR-66301/covid-19-rehberi.html.

Iba T, Levy JH, Connors JM, et al. The unique characteristics of COVID-19 coagulopathy. Crit Care. 2020 Jun 18;24(1):360. doi: 10.1186/s13054-020-03077-0.

Spiezia L, Boscolo A, Poletto F, et al. COVID-19- related severe hypercoagulability in patients admitted to intensive care unit for acute respiratory failure. Thromb Haemost 2020; 120: 998-1000.

Kollias A, Kyriakoulis KG, Dimakakos E, et al. Thromboembolic risk and anticoagulant therapy in COVID-19 patients: emerging evidence and call for action. Br J Haematol. 2020 Jun;189(5):846-847.

Published

January 13, 2022

License

License